-The Indian Express West Bengal is not new to chit fund scams. What is unique to the Saradha Group scandal is how it targeted the poorest and the most marginalised, leaving them on the verge of devastation. From 17-year-old agents who raised money from depositors to 50-year-old widows who invested money, the Saradha Group didn't discriminate in roping them in. Since the house of cards started collapsing, two agents and two...

-Reuters Millions of people in Maharashtra are at serious risk of hunger after two years of low rainfall, coupled with poor management of water resources, have left dams empty, farmland parched and cattle emaciated, aid agencies warned on Thursday. Maharashtra -- one of the country's biggest producers of sugar, pulses, cotton and soybeans -- is reeling from the worst drought in more than four decades after receiving less than 50 percent of...

-Live Mint Calls for govt action in case of Maharashtra should persuade even the staunchest supporters of benign govt intervention to do a rethink The drought situation in Maharashtra has attracted some amount of political attention, with the Union government announcing a Rs1,207 crore debt relief package in March. This is apart from relief measures announced by the state government. While experts have flayed the mismanagement of the situation by the...

-Bloomberg The corpse of Indian farmer Bengali Singh burned to ash atop a blazing funeral pyre on the banks of the river Ganges in 2006. Five years later, the dead man was recorded as being paid by India's $33 billion rural jobs program to dig an irrigation canal in Jharkhand state. Officials in his village and the surrounding region used at least 500 identities, including those of Singh, a disabled child of...

-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...